Phibro Animal Health Corp (PAHC) stock
PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 22/3046% below fair value
$34.92−0.10 (-0.29%)
Close on Nov 17, 2026Market cap $1.42BP/E 14.4Yield 1.37%
Phibro Animal Health r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was $24.55M, up 3.5% from the year before. Over ten years it grew 8.3% a year on average. The highest annual figure on record is $29.19M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $24.55M | +3.5% |
| FY2025 | Jun 30, 2025 | $23.73M | -18.7% |
| FY2024 | Jun 30, 2024 | $29.19M | +19.7% |
| FY2023 | Jun 30, 2023 | $24.40M | +17.1% |
| FY2022 | Jun 30, 2022 | $20.83M | +17.3% |
| FY2021 | Jun 30, 2021 | $17.76M | +29.3% |
| FY2020 | Jun 30, 2020 | $13.74M | +13.6% |
| FY2019 | Jun 30, 2019 | $12.09M | +21.0% |
| FY2018 | Jun 30, 2018 | $10.00M | +5.9% |
| FY2017 | Jun 30, 2017 | $9.44M | -14.4% |
| FY2016 | Jun 30, 2016 | $11.03M | +16.0% |
| FY2015 | Jun 30, 2015 | $9.51M | +15.8% |
| FY2014 | Jun 30, 2014 | $8.21M | +23.7% |
| FY2013 | Jun 30, 2013 | $6.64M | -7.7% |
| FY2012 | Jun 30, 2012 | $7.19M | – |
See a number that looks wrong?